ArticleLeukemia2022

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.

Catana Allert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.